ICP-MS与原子荧光光谱法测定化妆品中砷、汞含量的比较

目的通过对比ICP-MS法和原子荧光光谱法测定化妆品中砷和汞的含量,为化妆品中砷、汞的测定提供准确、可靠、简便的方法。方法采用微波消解技术,对仪器的工作条件进行优化,分别用ICP-MS法和原子荧光光谱法测定化妆品中砷和汞的含量。结果两种方法线性范围良好(r≥0.999 5),ICP-MS法中砷和汞的检出限分别为0.022和0.018 mg/kg,加标回收率在98.9%~102.3%之间,RSD在1.58%~1.90%之间;原子荧光光谱法中砷和汞的检出限分别为0.015和0.010 mg/kg,加标回收率在99.2%~100.9%之间,RSD在1.65%~2.15%之间;两种方法对标准物质的检测值均在规定的标准值范围内。结论两种方法测量的准确度和精密度都符合要求,若只测定砷和汞,且含量较低时,则推荐采用原子荧光光谱法。ICP-MS法具有简便准确、快速灵敏、稳定性好,线性范围宽的特点,更适用于大批量化妆品样品的多元素检测,且能够大大地提高检测效率。     

Kubelka-Munk模型下的兔血管对氦-氖激光的散射与吸收特性

测量了兔动脉和静脉对 He-Ne激光的反射和透射传输特性。实验采用两积分球系统及波长为632.8nm的He-Ne激光器,并根据测量数据及采用 Kubelka-Munk模型分析和计算了兔动脉和静脉组织对该长激光的吸收系数、散射系数及总的光强I（x）及前向散射通量i(x）和后向散射通量j(x）随厚度的变化情况。结果表明,兔动脉和静脉的漫反射率和透射率有明显差别,而且,动脉对激光的吸收系数明显较静脉的要小,而动脉对激光的散射系数却明显较静脉的要大,在动脉和静脉组织中总的光强I（x）及前向散射通量i(x）和后向散射通量j(x）随组织厚度的变化情况也有明显的区别。     

冰糖增加口服四环素吸收作用机理的初步研究

目的 :对中药冰糖增加口服四环素吸收作用机理进行初步的实验研究。方法 :参考 Masahiro Fukahori等介绍的方法 ,分别给大白鼠单独口服 (灌胃 )四环素或合并不同浓度冰糖溶液 (2 0 %、40 %、6 0 %、80 % )口服 (灌胃 )后 ,采用改进的荧光光度法测定血药浓度及肠内液药物浓度及含量 ,并称量与比较肠内容物量。结果 :合并使用冰糖可使大白鼠血中四环素的浓度明显提高 (P<0 .0 5 ) ,并在 2 0 %～ 6 0 %范围内呈明显的线性关系 ,而肠道内液四环素的含量则明显降低 (P<0 .0 5 )。但肠道内容物量与冰糖浓度并无明显相关性。结论 :冰糖可明显增加大白鼠口服四环素在肠道的吸收 ;而冰糖浓度对肠腔液体量没有明显影响。结果提示冰糖增加口服四环素吸收可能通过主动吸收过程。     

大黄-黄芪组分自微乳的制备及在体肠吸收特性研究

目的 研究大黄-黄芪多组分自微乳的处方与制备工艺,评价制剂质量,并考察其大鼠肠吸收特性。方法 通过溶解度实验、油相与乳化剂和助乳化剂配伍实验及伪三元相图的绘制,筛选出最优处方组成;并从自微乳的外观、形态、粒径、稳定性等方面对自微乳进行评价。通过大鼠在体单向肠灌流实验考察自微乳的肠吸收特性。结果 自微乳处方中油相为辛酸癸酸单双甘油酯、乳化剂为聚氧乙烯蓖麻油35、助乳化剂为乙二醇。在微乳形成区选择各辅料用量,采用适宜方法加入大黄总蒽醌及黄芪总皂苷制得的组分自微乳,外观均一透明,加水分散后形成黄色乳光的微乳液,透射电镜显微镜（transmission electron microscopy,TEM）下观察到微乳分散均匀,无黏连,呈大小均一圆球形乳滴;平均粒径为（33.01±0.12）nm、多分散指数（polydispersion index,PDI）为0.10±0.02、电位为（-10.10±1.00）m V;自微乳中大黄总蒽醌和黄芪总皂苷质量分数分别为6.29、8.80 mg/g。自微乳中大黄总蒽醌在十二指肠、空肠段的吸收速率常数（Ka）及表观吸收系数（Papp）较回肠段均有显著提高;黄芪...     

微波体模

用水、盐,聚氯乙烯粉和羧甲基纤维钠四种材料配制成一种适用的微波体模(模拟肌肉组织)。该体模的复介电系数在300～2500MHz范围内与实际人体肌肉组织的误差≤5％。这种体模的优点是材料立足国内,价廉,室温下配制,使用方便。本文也给出这种体模的温度特性,稳定性和热学特性,供电磁场生物效应和微波热疗等研究使用。     

磁场对高锰酸钾溶液吸收光谱的影响

目的:研究了磁场对高锰酸钾(KMnO4)吸收光谱的影响.结果:KMnO4溶液整体磁化及以磁化水为溶剂的KMnO4溶液吸收光谱与原溶液有所不同,其最大吸收波长紫移,二者紫移程度不同,而且吸收峰处吸光度有所增加.在一定时间内磁化时间越长,吸收峰处吸光度增加越多,磁场强度越大对吸收曲线影响越显著.说明在磁场作用下,水分子及高锰酸钾结构及状态的改变对高锰酸钾吸收光谱有影响.     

Differential Effects of Anionic,Cationic, Nonionic,and Physiologic Surfactants on the Dissociation, α-Chymotryptic Degradation,and Enteral Absorption of Insulin Hexamers

Various surfactants were investigated to compare their effects on insulin dissociation, -chymotryptic degradation, and rat enteral absorption. With a circular dichroism technique, sodium dodecyl sulfate (SDS) at a 5 mM concentration was found to completely dissociate procine-zinc insulin hexamers (0.5 mg/ml) into monomers. The catalytic activity of -chymotrypsin (0.5 µM) was also abolished by 5 mM SDS. When insulin was injected into the distal jejunum/ proximal ileum segment of the rat, 5 mM SDS greatly enhanced its pharmacological availability, from a negligible value to 2.8%. Being a cationic surfactant, hexadecyl trimethylammonium bromide (CTAB) also efficiently dissociated insulin hexamers at concentrations of 1–5 mM. However, extensive charge–charge interaction was observed below a CTAB concentration of 0.6 mM, leading to insulin precipitation at a molar CTAB:insulin ratio of 1:1 to 2:1. An -chymotryptic degradation study also revealed near-complete dissociation of insulin hexamers at 1 mM CTAB. Above 1 mM, however, CTAB acted as an enzyme inhibitor, most likely by means of charge repulsion. Enteral absorption studies showed a much lower pharmacological availability, only 0.29%. Nonionic surfactants such as Tween 80 and polyoxyethylene 9 lauryl ether were ineffective in dissociating insulin hexamers. Tween 80, at 5 mM, neither significantly altered the -chymotryptic degradation pattern nor enhanced the enteral absorption of insulin. The relative effectiveness of different species of bile salts on insulin hexamer dissociation appeared to be similar. Sodium glycocholate at a 30 mM concentration also significantly increased insulin pharmacological availability, to 2.3%. A morphological study did not reveal any significant alteration of the rat intestinal mucosal integrity after exposure to 5 mM SDS for 30 min. The results further emphasize the importance of the degree of insulin aggregation on its enteral transport.     

The Pharmacokinetics of Recombinant Human Relaxin in Nonpregnant Women After Intravenous,Intravaginal, and Intracervical Administration

The pharmacokinetics of recombinant human relaxin (rhRlx) after intravenous (iv) bolus administration and the absorption of rhRlx after intracervical or intravaginal administration were determined in nonpregnant women. The study was conducted in two parts. In part I, 25 women received 0.01 mg/kg rhRlx iv. After a minimum 7-day washout period, these women were dosed intracervically (n = 10) or intravaginally (n = 15) with 0.75 or 1.5 mg rhRlx, respectively, in 3% methylcellulose gel. Part II was a double-blind, randomized, three-way crossover study in 26 women. At 1-month intervals, each woman received one of three intravaginal treatments consisting of 0 (placebo), 1, or 6 mg rhRlx in 3% methylcellulose gel. The serum concentrations of relaxin following iv administration were described as the sum of three exponentials. The mean (±SD) initial, intermediate, and terminal half-lives were 0.09 ± 0.04, 0.72 ± 0.11, and 4.6 ± 1.2 hr, respectively. Most of the area under the curve was associated with the intermediate half-life. The weight-normalized clearance was 170 ± 50 mL/hr/kg. The observed peak concentration was 98 ± 29 ng/mL, and the weight-normalized initial volume of distribution was 78 ± 40 mL/kg, which is approximately equivalent to the serum volume. If central compartment elimination was assumed, the volume of distribution at steady state (V _ss/W) was 280 ± 100 mL/kg, which is approximately equivalent to extracellular fluid volume. V _ss/W could be as large as 1300 ± 400 mL/kg without this assumption. After intravaginal administration of the placebo gel, endogenous relaxin concentrations were evident (i.e., 20 pg/mL) in 9 of the 26 women (maximum concentrations, 23–234 pg/mL). A similar proportion of women (approximately 35–40%) exhibited measurable serum concentrations of relaxin following intravaginal rhRlx treatment; this proportion increased to 90% following intracervical rhRlx treatment. For both routes of administration, the maximum serum concentrations of relaxin were usually within the range of values observed for endogenous relaxin, suggesting that the absorption of rhRlx was minimal.     

Evidence for an Interaction Between the β-Blocker Pafenolol and Bile Salts in the Intestinal Lumen of the Rat Leading to Dose-Dependent Oral Absorption and Double Peaks in the Plasma Concentration–Time Profile

Pafenolol is a -blocker with unusual oral absorption properties. The blood concentration–time profile exhibits two peaks, and the bioavailability is low and dose dependent because of incomplete and nonlinear intestinal uptake. We addressed the question whether the intestinal absorption of pafenolol was affected by bile depletion in the gut lumen of rats. Further, the hypothesis that variable gastric emptying accounts for double peaks in blood was tested by duodenal administration of pafenolol. Following intraduodenal administration to rats with intact bile secretion, double peaks were observed in the blood concentration–time curve. The bioavailability was 6.8 ± 0.7% for the low dose (1 µmol/kg) and increased significantly to 28 ± 10% following the high duodenal dose (25 µmol/kg). These blood concentration–time profiles exclude interrupted gastric emptying as cause of the twin peaks. In bile duct-cannulated rats the intestinal absorption of the low dose (1 µmol/kg) was still poor (F = 10.7 ± 5.5%) and the blood concentration–time profile contained two peaks. Following administration of a high duodenal dose (25 µmol/kg) to rats with an almost bile-free small intestine, the absorption rate increased and the double-peak phenomenon disappeared in five of seven rats, while the bioavailability increased significantly, to 62 ± 27%. These results suggest that the low bioavailability of pafenolol is due to a complexation between bile and pafenolol in the gut lumen, preventing intestinal uptake in the major part of the small intestine. Further, such complex formation in the intestinal lumen may be the underlying mechanism of the double peaks observed in the blood concentration–time profile.     

Mechanism of Intestinal Absorption of Ranitidine and Ondansetron: Transport Across Caco-2 Cell Monolayers

We have investigated the transport of ranitidine and ondansetron across the Caco-2 cell monolayers. The apparent permeability coefficients (P _app) were unchanged throughout the concentration range studied, indicating a passive diffusion pathway across intestinal mucosa. No metabolism was observed for ranitidine and ondansetron during the incubation with Caco-2 cell monolayers. P _app values for ranitidine and ondansetron (bioavailability of 50 and 100% in humans, respectively) were 1.03 ± 0.17 × 10^–7 and 1.83 ± 0.055 × 10^–5 cm/sec, respectively. The P _app value for ranitidine was increased by 15- to 20-fold in a calcium-free medium or in the transport medium containing EDTA, whereas no significant change occurred with ondansetron, indicating that paracellular passive diffusion is not rate determining for ondansetron. Uptake of ondansetron by Caco-2 cell monolayers was 20- and 5-fold higher than that of ranitidine when the uptake study was carried out under sink conditions and at steady state. These results suggest that ranitidine and ondansetron are transported across Caco-2 cell monolayers predominantly via paracellular and transcellular pathways, respectively.